Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS
Inhalt archiviert am 2024-06-16

General synthetic strategies towards heterocyclic compounds via transition metal-catalysed reactions

Ziel

The reasoning behind the HCTMCR project is the need to develop mild and regioselective synthetic routes for the preparation of heterocyclic compounds. Decorated heterocyclic scaffolds are very important as biologically active compounds in the drug discover y process. However, many traditional routes for the synthesis of heterocycles are not compatible with a variety of functional groups or substitution patterns. The work carried out within the HCTMCR research project is geared towards the discovery of new, i nnovative synthetic strategies that will overcome existing limitations and will make accessible a multitude of heterocyclic structures. One approach to achieving this goal will be the application of modern organometallic reactions, such as metal-catalyzed cross-coupling reactions or olefin metathesis. Thus, heterocycles such as substituted 1H- and 2H-indazoles, benzimidazoles, 2H-chromenes or quinolines will be accessible in a regioselective manner, as well as annulated heterocycles of various ring sizes. I n addition, microwave technology will be applied when necessary to optimize the respective reaction time and yield. Another aspect of the investigations performed within the HCTMCR project will be the use of readily available starting materials in a conver gent fashion. Thus, regioselective aromatic C-H bond activation or the activation of chlorine-substituted aromatic systems as one of the reaction partners will be studied. If applicable, the development of multi-component pathways will be pursued.

Wissenschaftliches Gebiet (EuroSciVoc)

Thema/Themen

Aufforderung zur Vorschlagseinreichung

FP6-2002-MOBILITY-3
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

TOK - Marie Curie actions-Transfer of Knowledge

Koordinator

AVENTIS PHARMA DEUTSCHLAND GMBH
EU-Beitrag
Keine Daten
Adresse
Industriepark Hoechst, Building H821
FRANKFURT AM-MAIN
Deutschland
Gesamtkosten
Keine Daten